539 related articles for article (PubMed ID: 36547804)
1. The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development.
Yan W; Zheng Y; Dou C; Zhang G; Arnaout T; Cheng W
Mol Biomed; 2022 Dec; 3(1):48. PubMed ID: 36547804
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
5. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
6. The mmaA2 gene of Mycobacterium tuberculosis encodes the distal cyclopropane synthase of the alpha-mycolic acid.
Glickman MS
J Biol Chem; 2003 Mar; 278(10):7844-9. PubMed ID: 12502719
[TBL] [Abstract][Full Text] [Related]
7. Structure of the Essential
Kuhn ML; Alexander E; Minasov G; Page HJ; Warwrzak Z; Shuvalova L; Flores KJ; Wilson DJ; Shi C; Aldrich CC; Anderson WF
ACS Infect Dis; 2016 Aug; 2(8):579-591. PubMed ID: 27547819
[TBL] [Abstract][Full Text] [Related]
8. Designing novel inhibitors against cyclopropane mycolic acid synthase 3 (PcaA): targeting dormant state of
Verma J; Subbarao N
J Biomol Struct Dyn; 2021 Oct; 39(17):6339-6354. PubMed ID: 32715934
[No Abstract] [Full Text] [Related]
9. Lessons Learnt and the Way Forward for Drug Development Against Isocitrate Lyase from
Antil M; Gupta V
Protein Pept Lett; 2022; 29(12):1031-1041. PubMed ID: 36201276
[TBL] [Abstract][Full Text] [Related]
10. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets.
Harth G; Horwitz MA
J Exp Med; 1999 May; 189(9):1425-36. PubMed ID: 10224282
[TBL] [Abstract][Full Text] [Related]
11. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
12. Using a Heat Diffusion Model to Detect Potential Drug Resistance Genes of
Cui ZJ; Zhang WT; Zhu Q; Zhang QY; Zhang HY
Protein Pept Lett; 2020; 27(8):711-717. PubMed ID: 32167422
[TBL] [Abstract][Full Text] [Related]
13. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
14. Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.
Prezzemolo T; Guggino G; La Manna MP; Di Liberto D; Dieli F; Caccamo N
Front Immunol; 2014; 5():180. PubMed ID: 24795723
[TBL] [Abstract][Full Text] [Related]
15. Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria.
Pal R; Hameed S; Fatima Z
Biometals; 2019 Feb; 32(1):49-63. PubMed ID: 30430296
[TBL] [Abstract][Full Text] [Related]
16. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
Urban M; Šlachtová V; Brulíková L
Eur J Med Chem; 2021 Feb; 212():113139. PubMed ID: 33422979
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
18. Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.
McNeil MB; O'Malley T; Dennison D; Shelton CD; Sunde B; Parish T
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055263
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria.
Rodionova IA; Schuster BM; Guinn KM; Sorci L; Scott DA; Li X; Kheterpal I; Shoen C; Cynamon M; Locher C; Rubin EJ; Osterman AL
mBio; 2014 Feb; 5(1):. PubMed ID: 24549842
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
